A total of 7 patients with metastatic neuroendocrine tumors were treated, each with 4 doses of 177Lu-DOTATATE. The treatment response was evaluated in the form of biochemical response (tumor markers), imaging methods (somatostatin receptor scintigraphy, computed tomography, and magnetic resonance), ...
177Lu-labelled somatostatin analogues are successfully used in the treatment of neuroendocrine tumors in the peptide receptor radionuclide therapy (PRRT) [7]. The ideal nuclide properties of a half-life of 6.65 days and the maximum β-energy of 0.497 MeV [6] together with the carrier-free ...
A Parveen,A Fatima,IKIUSA Fatima - 《Nuclear Medicine Communications》 被引量: 0发表: 2023年 Re: [177Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study Lu-177-PSMA therapy177Lutetiumme...
This study presents a case of RrDTC who was treated with 177Lu-DOTATATE and 177Lu-PSMA, presumably as a first report in this regard. 展开 关键词: Lu DOTATATE prostate-specific membrane antigen radioiodine-refractory differentiated thyroid cancer ...
177Lu-Dotatate therapy for the treatment of metastatic neuroendocrine tumours in a patient on haemodialysis--dosimetric considerations. BJR Case Rep. 2015;1(3): 20150177.Kalogianni E, Ruiz DL, Corcoran BJ, Devlin LA, Vivian GC, ... E Kalogianni,Danielle Louise Ruiz,Benjamin James Corcoran,.....
Single-agent (Olaparib, Rucaparib, [ 177 Lu]Lu-DOTA-TOC) and combination treatment responses were determined in vitro via cell viability, clonogenic survival and γH2AX DNA damage assays. In vivo, we treated athymic nude mice bearing H69 or H446 xenografts with Olaparib, Rucaparib, or [ ...
The half-life of (177)Lu allowed significant tumor to normal tissue ratios to be obtained indicating that (177)Lu-tetraxetan-tetulomab could be suitable for clinical testing. The biological and effective half-life in blood was higher for (177)Lu-tetraxetan-tetulomab than for (177)Lu-...
All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [177Lu]Lu-PSMA-radioligand will be successful Trond Velde Bogsrud, Ola Engelsen, Thuy Thu Thi Lu, Andreas Stensvold, Derek R. Johnson, Brian J. Burkett, Ayse Tuba...
In this retrospective study, we analyzed the clinical outcome of lutetium-177 prostate-specific membrane antigen ( 177Lu-PSMA) in mCRPC patients with visceral metastasis. 展开 会议名称: ESMO Targeted Anticancer Therapies Virtual Congress (TAT) 2021 1-2 March 2021 会议时间: 2021/03/01 ...
[177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Midgut neuroendocrine tumors (NETs) are relatively rare and remarkably heterogeneous. Although recent developments for pancreatic NETs have brought multipl... M Daniel,Halperin,Arvind,... - 《Future Oncology》 被引量:...